---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-26-000028"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:25:25.208733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025

## Summary
- Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).
- Full-year 2025 revenue $796.9M, net income $30.4M, Adjusted EBITDA $270.5M (33.9% margin).
- Pharma Direct revenue beat prior outlook with over 40% year-over-year growth in 2025.
- CEO Wendy Barnes notes strong finish, rebranded Pharma Manufacturer Solutions as Pharma Direct.
- Adjusted Net Income Q4 $29.0M (14.9% margin); FY $126.1M (15.8% margin).

## SEC filing metadata
- accession: 0001809519-26-000028
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/0001809519-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/gdrx-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-26-000028
- JSON: https://secwatch.observer/filing/0001809519-26-000028.json
- Plain text: https://secwatch.observer/filing/0001809519-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.